Search - tctmd.com

Displaying 161 - 180 of 183

Sort: Relevancy | Date

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Shelley Wood

March 05, 2018

News Daily News

Obesity Robs People of CVD-Free Years and Ups the Risk of Dying Young

Michael O'Riordan

March 02, 2018

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Daily News

Surviving CVD: Obesity Offers No Protection for Those With New Onset Cardiac Events

Michael O'Riordan

December 07, 2017

News Conference News AHA 2017

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

Michael O'Riordan

November 17, 2017

News Daily News

More CVD and Stroke Drive Shorter Life Spans in African-Americans: AHA

Michael O'Riordan

October 24, 2017

News Conference News ESC 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Michael O'Riordan

August 29, 2017

News Daily News

Optimal Cardiovascular Health Not Offset by Poor Health as a Whole

Ashley Lyles

June 20, 2017

News Daily News

Growing Gap in CVD Risk Factor Control Between Rich and Poor

Michael O'Riordan

June 08, 2017

News Daily News

‘Sizeable’ Segment of Public, Even When at High CVD Risk, Feels No Need to Improve Health

Michael O'Riordan

May 04, 2017

News

Mortality and CVD Decline in Patients With Diabetes, but Biggest Strides Seen for Nonfatal Outcomes

Michael O'Riordan

April 13, 2017

News Daily News

Trans Fat Ban Led to Tangible CVD Benefits, New York State Analysis Shows

Michael O'Riordan

April 12, 2017

News Daily News

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Michael O'Riordan

April 04, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Daily News

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

Michael O'Riordan

February 03, 2017

News Daily News

Increased Sedentary Time Ups Risk for CVD, Diabetes, and Death, the AHA Says

Leah Lawrence

August 18, 2016

News Daily News

Weight Loss May Affect Diabetes Risk, but Not Future CVD Outlook

L.A. McKeown

August 04, 2016

News Daily News

The Billions Spent on Healthcare for Sedentary Citizens Warrants Global Response

L.A. McKeown

July 28, 2016

News Daily News

Sitting Pretty: Only Prolonged Sedentary Time Linked With Incident CVD Risk

Michael O'Riordan

July 15, 2016

News Daily News

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

Michael O'Riordan

June 30, 2016

Advertisement

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Obesity Robs People of CVD-Free Years and Ups the Risk of Dying Young

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Surviving CVD: Obesity Offers No Protection for Those With New Onset Cardiac Events

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

More CVD and Stroke Drive Shorter Life Spans in African-Americans: AHA

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Optimal Cardiovascular Health Not Offset by Poor Health as a Whole

Growing Gap in CVD Risk Factor Control Between Rich and Poor

‘Sizeable’ Segment of Public, Even When at High CVD Risk, Feels No Need to Improve Health

Mortality and CVD Decline in Patients With Diabetes, but Biggest Strides Seen for Nonfatal Outcomes

Trans Fat Ban Led to Tangible CVD Benefits, New York State Analysis Shows

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

Increased Sedentary Time Ups Risk for CVD, Diabetes, and Death, the AHA Says

Weight Loss May Affect Diabetes Risk, but Not Future CVD Outlook

The Billions Spent on Healthcare for Sedentary Citizens Warrants Global Response

Sitting Pretty: Only Prolonged Sedentary Time Linked With Incident CVD Risk

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content